# US 2015/0174157 A1 · INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174157 A1
- Document ID: US20150174157A1
- Status: Published application
- Kind: A1
- Application number: 14/634,440
- Filed: 2015-02-27
- Published: 2015-06-25
- Earliest claimed: 2007-06-15
- Assignees: Kaohsiung Medical University
- Applicants: Kaohsiung Medical University
- Inventors: Ing-Jun CHEN
- Web page: https://patentgrep.com/patent/US20150174157A1

## CPC

- A61K 31/785: Polymers containing nitrogen
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/351: not condensed with another ring
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/717: Celluloses
- A61K 31/727: Heparin; Heparan
- A61K 31/728: Hyaluronic acid
- A61K 31/734: Alginic acid
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 31/765: Polymers containing oxygen
- A61K 31/78: of acrylic acid or derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for treating a disease is disclosed. The method includes steps of providing a subject in need thereof; and administering one selected from a group consisting of Piperazinyl Analogs and Piperazinyl Complex Analogs compound represented by formula II or formula III, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage between 1 and 5.0 milligrams per kilogram of body weight, in a liquid mist, dry powder or aerosolized formulation.

## Claims

### Claim 1

A method for inhibiting a pulmonary inflammation, comprising steps of:
providing a subject in need thereof; and
administering a pharmaceutical composition of a KMUPs complex compound selected from a group consisting of KMUPs-RX complex compound, KMUPs-RX-RX complex compound and administer to the subject a dosage between 1 and 5.0 milligrams per kilogram of body weight,
wherein KMUPs include KMUP-1, KMUP-2, KMUP-3 and KMUP-4:
RX includes a carboxylic group selected from a group consisting of a Statin analogue, a Co-polymer, a poly-γ-polyglutamic acid derivative, ascorbic acid, an oleic acid, a phosphoric acid, a citric acid, a nicotinic acid and a sodium CMC; and
the pulmonary inflammation comprises one selected from a group consisting of a pulmonary artery hypertension, a pulmonary artery proliferation, an allergic pulmonary vascular inflammation, a physiological activity of a lung cell, a vascular remodeling inhibiting disease and a combination thereof.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the pulmonary inflammation comprises one selected from a group consisting of an obstructive pulmonary disease, a pulmonary artery hypertension, pulmonary artery proliferation, an allergic pulmonary vascular inflammation, a physiological activity of a lung cell, a vascular remodeling inhibiting disease and a combination thereof.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein KMUP-1 is 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, KMUP-2 is 7-[2-[4-(2-methoxybenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, KMUP-3 is 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine and KMUP-4 is 7-[2-[4-(2-nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the KMUPs-RX complex compound is one selected from a group consisting of KMUP-1-Atorvastatin complex compound, KMUP-2-Atorvastatin complex compound, KMUP-3-Atorvastatin complex compound, KMUP-4-Atorvastatin complex compound, KMUP-1-Cerivastatin complex compound, KMUP-2-Cerivastatin complex compound, KMUP-3-Cerivastatin complex compound, KMUP-4-Cerivastatin complex; KMUP-1-Fluvastatin complex compound, KMUP-2-Fluvastatin complex compound, KMUP-3-Fluvastatin complex compound, KMUP-4-Fluvastatin complex compound, KMUP-1-Lovastatin complex compound, KMUP-2-Lovastatin complex compound, KMUP-3-Lovastatin complex compound, KMUP-4-Lovastatin complex; KMUP-1-Mevastatin complex compound, KMUP-2-Mevastatin complex compound, KMUP-3-Mevastatin complex compound, KMUP-4-Mevastatin complex compound, KMUP-1-Pravastatin complex compound, KMUP-2-Pravastatin complex compound, KMUP-3-Pravastatin complex compound, KMUP-4-Pravastatin complex compound, KMUP-1-Rosuvastatin complex compound, KMUP-2-Rosuvastatin complex compound, KMUP-3-Rosuvastatin complex compound, KMUP-4-Rosuvastatin complex compound, KMUP-1-Simvastatin complex compound, KMUP-2-Simvastatin complex compound, KMUP-3-Simvastatin complex compound, KMUP-4-Simvastatin complex; KMUP-1-ascorbic acid complex compound, KMUP-2L-ascorbic acid complex compound, KMUP-3L-ascorbic acid complex compound, KMUP-4L-ascorbic acid complex; KMUP-1-phosphoric acid complex compound, KMUP-2-phosphoric acid complex compound, KMUP-3-phosphoric acid complex compound, KMUP-4-phosphoric acid complex; KMUP-1-CMC complex compound, KMUP-2-CMC complex compound, KMUP-3-CMC complex compound, KMUP-4-CMC complex compound, KMUP-1-hyaluronic complex compound, KMUP-2-hyaluronic complex compound, KMUP-3-hyaluronic complex compound, KMUP-4-hyaluronic complex compound, KMUP-1-polyacrylic complex compound, KMUP-2-polyacrylic complex compound, KMUP-3-polyacrylic complex compound, KMUP-4-polyacrylic complex compound, KMUP-1-Eudragit complex compound, KMUP-2-Eudragit complex compound, KMUP-3-Eudragit complex compound, KMUP-4-Eudragit complex; KMUP-1-polylactide complex compound, KMUP-2-polylactide complex compound, KMUP-3-polylactide complex compound, KMUP-4-polylactide complex; KMUP-1-polyglycolic complex compound, KMUP-2-polyglycolic complex compound, KMUP-3-polyglycolic complex compound, KMUP-4-polyglycolic complex compound, KMUP-1-dextran sulfate complex compound, KMUP-2-dextran sulfate complex compound, KMUP-3-dextran sulfate complex compound, KMUP-4-dextran sulfate complex compound, KMUP-1-heparan sulfate complex compound, KMUP-2-heparan sulfate complex compound, KMUP-3-heparan sulfate complex compound, KMUP-4-heparan sulfate complex compound, KMUP-1-alginate complex compound, KMUP-2-alginate complex compound, KMUP-3-alginate complex compound, KMUP-4-alginate complex compound, KMUP-1-γ-PGA complex compound, KMUP-2-γ-PGA complex compound, KMUP-3-γ-PGA complex compound, KMUP-4-γ-PGA complex compound, KMUP-1-APA complex compound, KMUP-2-APA complex compound, KMUP-3-APA complex compound and KMUP-4-APA complex compound.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the administration is performed by one selected from an oral, an injection, an inhalation and a topical administration.

### Claim 6 (depends on 5)

The method as claimed in claim 5, administering by inhalation or nasal route to a patient in need thereof a therapeutically effective amount of one of a KMUPs complex compound and a pharmaceutical composition in propellant gases.

### Claim 7 (depends on 5)

The method as claimed in claim 5, administering by inhalation or nasal route to a patient in need thereof a therapeutically effective amount of one of a KMUPs complex compound and a pharmaceutical composition in dry powder.

### Claim 8 (depends on 5)

The method as claimed in claim 5, administering by inhalation or nasal route to a patient in need thereof a therapeutically effective amount of one of a KMUPs complex compound and a pharmaceutical composition in liquid mist inhaler.

### Claim 9

A combination method for inhibiting a pulmonary inflammation, comprising steps of:
providing a subject suffering from the pulmonary inflammation; and
administering a combination of one selected from a group consisting of Piperazinyl Analogs compounds, and administrating a pharmaceutically effective amount of a compound selected from a group consisting of Statin analogue, a Co-polymer, a poly-γ-polyglutamic acid derivative, ascorbic acid, an oleic acid, a phosphoric acid, a citric acid, a nicotinic acid and a sodium CMC, thereof to the subject in need thereof in a combination dosage between 1 and 5.0 milligrams per kilogram of body weight.

### Claim 10 (depends on 9)

The combination method as claimed in claim 9, wherein the pulmonary inflammation comprises one selected from a group consisting of an obstructive pulmonary disease, a pulmonary artery hypertension, pulmonary artery proliferation, an allergic pulmonary vascular inflammation, a physiological activity of a lung cell, a vascular remodeling inhibiting disease and a combination thereof.

### Claim 11 (depends on 9)

The combination method as claimed in claim 9, wherein the statins analogues is one selected from a group consisting of Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pravastatin, Rosuvastatin, Simvastatin, Pramastatinic acid and its pharmaceutical acceptable salts.

### Claim 12 (depends on 9)

The combination method as claimed in claim 9, wherein the Co-polymers is one selected from a group consisting of a hyaluronic acid, a polyacrylic acid, a polymethacrylates (PMMA), an Eudragit, a dextran sulfate, a heparan sulfate, a polylactic acid or polylactide (PLA), a polylactic acid sodium (PLA sodium) and a polyglycolic acid sodium (PGA sodium).

### Claim 13 (depends on 9)

The combination method as claimed in claim 9, wherein the Poly-γ-polyglutamic acid (γ-PGA) derivative is one selected from a group consisting of an alginate sodium, a poly-γ-polyglutamic acid sodium (γ-PGA sodium), a poly-γ-polyglutamic acid (γ-PGA) and an alginate-poly-lysine-alginate (APA).

### Claim 14 (depends on 9)

The combination method as claimed in claim 9, wherein the administration is performed by one selected from an oral, an injection, an inhalation and a topical administration.

### Claim 15 (depends on 9)

The combination method as claimed in claim 9, administering by inhalation or nasal route to a patient in need thereof a therapeutically effective amount of one of a Piperazinyl Analogs compound and a pharmaceutical composition in propellant gases.

### Claim 16 (depends on 9)

The combination method as claimed in claim 9, administering by inhalation or nasal route to a patient in need thereof a therapeutically effective amount of one of a Piperazinyl Analogs compound and a pharmaceutical composition in dry powder.

### Claim 17 (depends on 9)

The combination method as claimed in claim 9, administering by inhalation or nasal route to a patient in need thereof a therapeutically effective amount of one of a Piperazinyl Analogs compound and a pharmaceutical composition in a liquid mist inhaler.

### Claim 18 (depends on 9)

The combination method as claimed in claim 9, wherein Piperazinyl Analogs is one selected from a group consisting of KMUPs derivative compounds and Sildenafil Analogs compounds.

### Claim 19 (depends on 18)

The combination method as claimed in claim 18 wherein the KMUPs derivative compounds include KMUP-1, KMUP-2, KMUP-3, KMUP-4 and a pharmaceutical acceptable salts and a combination thereof.

### Claim 20 (depends on 18)

The combination method as claimed in claim 18, wherein Sildenafil Analogs compounds include Sildenafil, Hydroxyhomosildenafil, Desmethylsildenafil, Acetidenafil, Udenafil, Vardenafil and Homosildenafil.
